PROtein S100B for Mild Trauma of the HEad in Emergency Patients

Completed

• Conditions: Mild Traumatic Brain Injury
• Interventions: Biological: S100B protein dosage; Other: Brain CT scan

• Registration Number: NCT03313505
• Lead Sponsor: Centre Hospitalier Princesse Grace

Brief Summary

Brain injury is a frequent purpose for consultation in emergency services. Management of brain injury is time and resource consuming, combining clinical monitoring and imaging.

The stage prior to the management of the victims of brain injury is stratification of the severity, potential or proven.

Severe brain injury requires emergent brain CT-scan, ideally within one hour of the first medical contact. Patients requiring this strategy present with focused neurological deficit, Glasgow score \<15 to 2 hours after the trauma, suspicion of open fracture of the skull or dish pan fracture, any signs of fracture of the skull base (hemotympanum, bilateral peri-orbital ecchymosis), otorrhea or rhinorrhea of cerebrospinal fluid, more than one episode of vomiting in adults, and posttraumatic convulsion. Patients benefiting from anticoagulant therapy are included in this category.

Victims of brain injury that do not fall into this category are considered less critical.

By definition, mild traumatic brain injury :

* a trauma of the cephalic extremity :

* whose Glasgow score (30 min after the trauma or during the consultation) is 13-15,

* associated with one or more of the following: confusion; disorientation; loss of consciousness of 30 min or less; post-traumatic amnesia of less than 24 hours; other transient neurological abnormalities (focal signs, epileptic seizures, non-surgical intracranial lesion).

Among these patients, some are considered at risk of developing intracerebral lesions. Nevertheless, it should be noted that the prevalence of hemorrhagic complications is radically different between patients with a Glasgow score of 13 and those with a score of 15. Thus, the recommendations suggest a brain scan without injection of contrast media within 4 to 8 hours for patients with the following characteristics :

* a retrograde amnesia of more than 30 minutes,

* a loss of consciousness or amnesia associated with:

* either a risk mechanism (pedestrian overturned by a motor vehicle, ejection of a vehicle, falling by more than one meter),

* or an age\> 65 years,

* or coagulation disorders, including the use of platelet aggregation therapy. Patients who fall outside this definition are considered low risk of complication and should not benefit of imaging.

Data from the scientific literature show that an early brain CT-scan allows identification of post-traumatic lesions in this population. Nevertheless, organizational problems, including the availability of the imaging, radiation, and disruption of surveillance related to patient displacement, are limitations to this strategy. In contrast, the low cost-effectiveness of CT scan is often advocated in patients with mild traumatic brain injury. For example, in the Octopus study, 52 of 1316 patients who received CT scan after mild head trauma had an intracerebral lesion. Among these patients, 39 (3%) had intracerebral lesion related to trauma; for 13 (1%) patients, the link with the trauma was uncertain.

In fact, the search of alternatives for a safer, more conservative, more efficient practice, one of the objectives of which is to limit the undue use of cerebral scanning. Thus, many teams have been interested in the use of biological variables to guide the decision to use imagery.

Among candidate biomarkers, the S100B protein has been the subject of many evaluations which allow it to be used in current practice. Indeed, the increase of the S100B protein carried out within 3 hours following a mild head trauma makes it possible to identify the patients at risk of intracerebral lesion and to target the indications of imaging.

The purpose of the registry is to describe the use, interpretation and performance of the S100B protein in its use at bedside in emergency medicine.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-10-13
• Study First Submitted QC: 2017-10-13
• Study First Posted: 2017-10-18
• Study Start: 2018-05-14
• Status Verified: 2021-07
• Primary Completion: 2021-07-15
• Study Completion: 2021-07-22
• Last Update Submitted: 2021-07-28
• Last Update Posted: 2021-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 787

Inclusion Criteria

• Adult Patients

• Victims of mild head trauma at risk of complication :

  o Adult patients with head trauma with:

• retrograde amnesia of more than 30 minutes, or

• loss of consciousness or amnesia of the facts associated with:

  • Either a risky mechanism (pedestrian overturned by a motor vehicle, ejection of a vehicle, drop of more than one meter),
  • either An age> 65 years,
  • Either clotting disorders, including platelet aggregation therapy.
  • either Glasgow Score to 15

• Admitted to the emergency department within three hours of the traumatic event.

Exclusion Criteria

• Refusal to participate at the study
• Patients with obstacle to 7 days follow up
• Pregnant women
• Patients not subject to an health insurance scheme in France or Monaco.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients who had been tested for S100B protein	S100B protein dosage	-
Patients who have benefited from another strategy	Brain CT scan	-

Primary Outcome Measures

Name	Time	Method
Evaluation of the number of brain CT-scan saved in patients who have been tested for S100B protein	53 weeks	Percentage (%)

Secondary Outcome Measures

Name	Time	Method
Intensive treatment comparison of the patients included in the centers that carried out an "intensive implementation" of the use of the S100B protein and those included in the centers that provided the S100B protein	53 weeks	Percentage (%)
Comparison of supported patients with S100B protein assay or without S100B protein assay	53 weeks	Percentage (%)
Quantification and evaluation of deviations to the algorithm	53 weeks	Percentage (%)

Trial Locations

Locations (15)

Centre Hospitalier Universitaire de Clermont-Ferrand; 🇫🇷 Clermont-Ferrand, France

Hospices Civils de Lyon - Pôle Est; 🇫🇷 Lyon, France

AP-HM La Timone; 🇫🇷 Marseille, France

CHU de Strasbourg; 🇫🇷 Strasbourg, France

Centre Hospitalier Universitaire de Nice, Hôpital Pasteur; 🇫🇷 Nice, France

Centre Hospitalier Princesse Grace; 🇲🇨 Monaco, Monaco

Hôpital Charles Nicolle; 🇫🇷 Rouen, France

HIA Sainte Anne; 🇫🇷 Toulon, France

Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan; 🇫🇷 Toulouse, France

Centre Hospitalier Universitaire de Poitiers; 🇫🇷 Poitiers, France

AP-HP Centre Hospitalier Universitaire Henri-Mondor; 🇫🇷 Créteil, France

Centre Hospitalier de Metz-Thionville; 🇫🇷 Metz, France

Centre Hospitalier Universitaire de Nîmes - Hôpital Carémeau; 🇫🇷 Nîmes, France

AP-HP Nord Lariboisière; 🇫🇷 Paris, France

AP-HP Sud Pitié-Salpêtrière; 🇫🇷 Paris, France